Full history for every metric is available with a Kvantra account
ASLAN Pharmaceuticals Limited (ASLN)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 3 | 0 | 0 | 0 | 12 | 12 |
| Operating profit | $m | -44 | -35 | |||||
| Net profit | $m | -42 | -47 | -18 | -35 | -51 | -44 | -35 |
| EPS reported | $ | -10.76 | -7.92 | |||||
| Operating cashflow per share | $ | -11.27 | -11.27 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -11.28 | -11.28 | |||||
| Free cash flow | $m | -46 | -6 | |||||
| Net debt | $m | 6 | 8 | |||||
| Book value equity | $m | -13 | -18 | |||||
| Book value per share | $ | -3.23 | -3.85 | |||||
| Number of shares | m | 4.11 | 4.67 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.29 | -43.26 | |||||
| P/S LTM | x | 1.43 | 64.76 | |||||
| P/FCF LTM | x | -0.37 | -124.59 | |||||
| EV/EBITDA LTM | x | -0.58 | -25.38 | |||||
| EV/Sales LTM | x | 1.90 | 65.44 | |||||
| Earnings Yield LTM | % | -257.24% | -1792.1% | |||||
| FCF Yield | % | -269.75% | -0.80% | |||||
| Quality | ||||||||
| ROE | % | 332.81% | 1796.9% | |||||
| ROIC | % | -323.05% | -323.05% | |||||
| Operating margin | % | -364.46% | -364.46% | |||||
| Gross margin | % | 97.10% | 97.10% | |||||
| FCF/Sales | % | -386.42% | -386.42% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.73 | -0.23 | |||||
| Net Debt/EBITDA | x | -0.14 | -0.14 | |||||
| EBIT/Net interest | x | -10.11 | -10.11 | |||||
| Net debt/market cap | % | 32.42% | 1.04% | |||||
| Net debt/Equity | x | -0.42 | -0.45 | |||||
| Gross debt/equity | x | -2.02 | -1.48 | |||||
Company overview
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ASLAN Pharmaceuticals Limited (ASLN)
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free